• 1
    Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989; 11: 954963.
  • 2
    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929936.
  • 3
    Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501508.
  • 4
    Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009; 3: 4791.
  • 5
    Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009; 30: 253264.
  • 6
    Gordon MA. Salmonella infections in immunocompromised adults. J Infect. 2008; 56: 413422.
  • 7
    Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 14171423.
  • 8
    Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010; 105: 12311238.
  • 9
    Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. 2008; 8: 17871795.
  • 10
    Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59: 127.
  • 11
    Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. BMJ. 1996; 312: 430434.
  • 12
    Lutwick LI. Infections in asplenic patients. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p 38653873.
  • 13
    Roukens AH, van Dissel JT, de Fijter JW, et al. Health preparations and travel-related morbidity of kidney transplant recipients traveling to developing countries. Clin Transplant. 2007; 21: 567570.
  • 14
    Neuvonen PJ, Olkkola KT. Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses. Med Toxicol Adverse Drug Exp. 1988; 3: 3358.
  • 15
    The immunocompromised traveller. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2007; 33: 124.
  • 16
    Dutch national guidelines on travel medicine. LCR Committee, 2010: 1544.
  • 17
    Centre for Evidence Based Medicine, Oxford. Levels of evidence and grades of recommendation. Available at: Accessed August 31, 2011.
  • 18
    Cobelens FG, van DH, Draayer-Jansen IW, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet. 2000; 356: 461465.
  • 19
    Crohn en Colitis Ulcerosa Vereniging Nederland (CCUVN). Available at: Accessed February 28, 2011.
  • 20
    Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749753.
  • 21
    Crohn's & Colitis Foundation of America. Traveling with IBD. 2009. Available at: Accessed April 11, 2011.
  • 22
    Travelling with Inflammatory Bowel Disease (Or …The Guts to Travel?). A Special Report By Dr Deborah Mills. Available at:, Accessed April 11, 2011.
  • 23
    Traveling With IBD. Take Your IBD on the Road — After Some Preparation. By Amber J. Tresca, September 20, 2010. Available at:, Accessed April 11, 2011.
  • 24
    Ericsson CD. Travellers with pre-existing medical conditions. Int J Antimicrob Agents. 2003; 21: 181188.
  • 25
    McCarthy AE, Mileno MD. Prevention and treatment of travel-related infections in compromised hosts. Curr Opin Infect Dis. 2006; 19: 450455.
  • 26
    Baaten GG, Geskus RB, Kint JA, et al. Symptoms of infectious diseases in immunocompromised travellers: a prospective study with matched controls. J Travel Med. 2011; 18: 318326.
  • 27
    Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011; 364: 13261333.
  • 28
    Mow WS, breu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004; 2: 309313.
  • 29
    Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 27992806.
    Direct Link:
  • 30
    Stark K, Gunther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis. 1999; 180: 20142017.